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Response to Masked Hypertension in Untreated and 
Treated Patients With Diabetes Mellitus: Attractive But 
Questionable Interpretations and Response to Is Masked 
Hypertension Related to Diabetes Mellitus?
We agree with Drs Sobiczewski and Wirtwein that a self-
reported diagnosis of diabetes mellitus or the use of antidiabetic 
drugs may not provide an accurate prevalence of the disease, in 
particular because of the somewhat different criteria used in the 
11 cohorts included in the International Database on Ambulatory 
blood pressure in relation to Cardiovascular Outcomes (IDACO).1 
However, misclassification of diabetes mellitus should weaken, 
not strengthen, the results of our study. In reply to the comments 
on ambulatory blood pressure (BP) measurement, we standard-
ized the definitions of daytime and nighttime across cohorts tak-
ing into account the differences in the pattern of daily activities 
between Europe and Asia (see Expanded Methods in the online-
only Data Supplement).1 Moreover, to account for the varying 
intervals between ambulatory BP readings, we computed time-
weighted BP means of the daytime BP (see Expanded Methods 
in the online-only Data Supplement).1 In terms of the compari-
son of cardiovascular risk between untreated diabetic patients 
with masked hypertension versus untreated diabetic patients 
with stage-1 hypertension,1 we wish to correct a misconception. 
The risk was equal with a hazard ratio of 1.07 (95% confidence 
interval, 0.58–1.98; P=0.82). In addition, the hypothesis that we 
may have underdiagnosed untreated masked hypertension in the 
patients with diabetes mellitus by using the daytime rather than 
the nighttime ambulatory BP was put to the test. Of the 229 
untreated diabetic patients with normotension by office reading, 
there were 67 (29.3%) versus 56 (24.5%) patients with masked 
hypertension as identified by elevated daytime versus nighttime 
BP, respectively. However, use of daytime versus nighttime BP to 
define masked hypertension led to discrepant diagnoses in 22.2% 
of the untreated patients with diabetes mellitus. There is abundant 
evidence in the diabetic and other high-risk hypertensive states 
that nocturnal BP, alone or together with daytime BP, is a superior 
predictor of cardiovascular risk than daytime BP alone.2–4 In the 
current study in untreated patients with diabetes mellitus, masked 
hypertension, either defined using daytime BP (hazard ratio, 1.96; 
confidence interval, 0.97–3.97; P=0.059) or nighttime BP (hazard 
ratio, 3.44; confidence interval, 1.68–7.06; P<0.001), predicted 
increased cardiovascular risk as compared with sustained normo-
tension. However, confidence intervals were wide and overlapping 
probably because of the relatively small number of events in these 
subgroups. This limitation was noted in our discussion.1
Doumas et al raised several issues. The figure used in the 
Clinical Implications section,5 which accompanied our publica-
tion,1 addressed many of these issues. First, in both patients with 
and without diabetes mellitus, there was a significantly greater car-
diovascular risk in the untreated masked hypertensive than in the 
untreated normotensive comparator group. With adjustment for 
center, sex, and age, the P value was 0.0091. Second, we hypoth-
esized that antihypertensive treatment converted cases of sus-
tained hypertension into treated masked hypertension. This may 
explain the higher prevalence of masked hypertension in treated 
versus untreated patients. Similarly, treatment may have converted 
masked hypertension into sustained normotension. This resulted in 
a higher rate of cardiovascular events during the 11-year follow-up 
in both treated masked hypertensives and treated normotensives as 
compared to the untreated normotensive comparator group with 
no difference in cardiovascular event rate between treated masked 
hypetensives and treated normotensives. Third, we postulate that 
the greatest reduction in cardiovascular risk occurs when antihy-
pertensive treatment dosage is titrated upward or additional anti-
hypertensive agents are added, until the majority of patients with 
masked hypertension reached sustained normotension, that is, 
when the ambulatory BP was normalized. Not surprisingly, nor-
malization of ambulatory BP with treatment did not eliminate the 
lifetime cardiovascular burden associated with previous elevated 
BP, nor did it correct other cardiometabolic risk factors that clus-
ter with the hypertensive state.6 Thus, the cardiovascular risk in 
a patient with treated, normalized BP is always greater than in 
an untreated subject with the identical BP.6 Fourth, antihyperten-
sive treatment increases the prevalence of masked hypertension 
by decreasing conventional BP versus ambulatory BP by a ratio 
of ≈3 to 2.7 This further strengthens our hypothesis that subjects 
who started with untreated sustained hypertension were converted 
by treatment into masked hypertension because conventional BP 
normalized, whereas the ambulatory BP remained elevated. Fifth, 
because antihypertensive therapy decreases conventional BP more 
than the ambulatory BP, the reliance on conventional BP as a target 
treatment goal will result in suboptimal reduction in the cardio-
vascular event rate. We agree with Doumas et al and so stated in 
our limitation section: “the confidence intervals around the hazard 
ratios comparing the risks in masked hypertensives versus normo-
tensives and stage 1 and stage 2 hypertensives were wide, reflecting 
limited statistical power to accurately assess differences between 
these subgroups.”1 Furthermore, the larger nondiabetic IDACO 
population of patients with masked hypertension was supportive 
of all the above conclusions and with more robust significant P 
values.1 Importantly, follow-up BP data and more information on 
the type of antihypertensive therapy would have been useful, but 
the absence of this information did not weaken the conclusions of 
our study.1 Similarly, we agree that 24-hour ambulatory BP cannot 
be justified on a cost–benefit basis for every normotensive dia-
betic patient, as has been concluded by other investigators.8 As 
we suggested in the Perspectives,1 home BP monitoring may be a 
satisfactory substitute for ambulatory BP monitoring in low-risk 
patients.9 Furthermore, others have concluded that patients with 
diabetes mellitus and masked hypertension have sufficient cardio-
vascular risk factors, frequently including target organ damage, 
to warrant antihypertensive therapy.10,11 However, we agree with 
Doumas et al that the benefit of treatment of masked hypertension 
in patients with and without diabetes mellitus must be confirmed 
by randomized controlled trials. Finally, as stated in our recent 
IDACO study,1 our conclusions are hypothesis generating and 
need verification by further studies.
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